Objective:To explore the efficacy and safety of Bevacizumab combined with XELOX chemotherapy regimen in the treatment of patients with metastatic colorectal cancer.Method:A total of 60 patients with metastatic colorectal cancer admitted to the General Hospital of Huainan East Hospital Group from June 2020 to June 2022 were randomly selected.They were divided into control group and observation group according to random number table method,with 30 cases in each group.The control group was given XELOX chemotherapy regimen,and the observation group was given Bevacizumab Injection based on the control group.The clinical efficacy,tumor markers,immune function,quality of life before and after treatment,adverse reactions and survival rate were compared between the two groups.Result:The total remission rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the carcinoembryonic antigen(CEA),serum amyloid A protein(SAA),carbohydrate antigen 19-9(CA19-9)levels in the two groups were lower than those before treatment,and CEA,SAA and CA19-9 levels in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).After treatment,CD4+ and CD4+/CD8+ increased in both groups,while CD8+ decreased,CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group,and CD8+ was lower than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The survival rate of observation group was higher than that of control group,and the difference was statistically significant(P<0.05).After treatment,the scores of social function,psychological function,physiological function and physical function of the two groups were higher than those before treatment,and the scores of social function,psychological function,physiological function and physical function of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusion:The combination of Bevacizumab and XELOX chemotherapy regimen can improve the clinical efficacy and survival rate,enhance immune function and reduce the level of tumor markers.
维普
万方数据